10-QPeriod: Q1 FY2001

BIOGEN INC. Quarterly Report for Q1 Ended Mar 31, 2001

Filed May 15, 2001For Securities:BIIB

Summary

Idec Pharmaceuticals Corporation (now Biogen Inc.) has reported a significant improvement in its financial performance for the first quarter of 2001 compared to the same period in 2000. Total revenues more than doubled, driven primarily by a substantial increase in "Revenues from unconsolidated joint business," largely attributable to higher copromotion profits from Rituxan. This growth reflects increased market penetration and a favorable shift in the profit-sharing formula with Genentech. The company also demonstrated strong operational cash flow generation, leading to a healthy increase in its cash and cash equivalents. Despite increased research and development and selling, general, and administrative expenses, the company maintained profitability, achieving positive basic and diluted earnings per share. Management anticipates continued expense growth related to pipeline development and potential commercialization of ZEVALIN, but believes current resources are sufficient for the foreseeable future.

Key Highlights

  • 1Total revenues surged to $56.5 million in Q1 2001 from $27.0 million in Q1 2000, more than doubling year-over-year.
  • 2Revenues from unconsolidated joint business increased significantly to $48.6 million from $21.9 million, driven by higher copromotion profits from Rituxan.
  • 3The company reported net income of $20.8 million in Q1 2001, a substantial improvement from a net loss of $4.3 million in Q1 2000.
  • 4Basic earnings per share were $0.14 in Q1 2001, compared to a loss of $0.03 in Q1 2000.
  • 5Cash and cash equivalents increased to $415.4 million as of March 31, 2001, from $89.0 million as of March 31, 2000.
  • 6Research and development expenses increased by approximately 50% to $22.1 million, reflecting ongoing pipeline development.
  • 7The company received a Complete Review Letter from the FDA for its ZEVALIN BLA, outlining additional information required for review.

Frequently Asked Questions

The primary driver of the revenue increase is "Revenues from unconsolidated joint business," which more than doubled. This is largely due to a substantial increase in copromotion profits from Rituxan, attributed to increased market penetration and a more favorable profit-sharing tier with Genentech starting in Q1 2001.

The company received a Complete Review Letter from the FDA for its ZEVALIN BLA in May 2001. The FDA outlined additional information and analysis needed related to Clinical and Chemistry, Manufacturing, and Controls (CMC). The company believes it can address these requests without new clinical trials and plans to submit its response by mid-July 2001.

The company has transitioned from a net loss of $4.3 million in the first quarter of 2000 to a net income of $20.8 million in the first quarter of 2001. This significant improvement is a result of increased revenues and improved operational efficiency.

Key risks include significant reliance on Rituxan sales for revenue, potential fluctuations in operating results due to various factors (milestones, sales, clinical trial progress), uncertain outcomes of clinical trials, challenges in developing and commercializing new products like ZEVALIN, limited manufacturing experience and reliance on third parties, intense competition, and intellectual property protection issues.